Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02602470 · ClinicalTrials.gov registry record
Preferences & Treatment Satisfaction Drivers in Rosacea Patients
A clinical trial, sponsored by LEO Pharma.
- Completed
- Registry status
- 206
- Enrollment target
NCT02602470: Completed study, sponsored by LEO Pharma.
NCT02602470 is a clinical trial that has completed, run by LEO Pharma. The registered enrollment target is 206 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02602470 has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- 206 participants
- Enrollment target
Study Summary
To survey patients with rosacea about their rosacea treatment preferences as well as to assess potential drivers of rosacea treatment satisfaction.
Primary Outcome
Assessed from the Rosacea Treatment Preference Questionnaire: Rated on a scale of 0 to 10, with 0 meaning not at all important and 10 meaning extremely important
Interventions
- DRUG Metronidazole cream
- DRUG Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)
- DRUG Azelaic Acid Cream
- DRUG Metronidazole gel
- DRUG Metronidazole Emulsion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2015-01-08 |
| Est. Completion | 2016-03-10 |
What the finished NCT02602470 record still lists
NCT02602470 is an observational study that tracks outcomes without assigning an intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 5 interventions - of which Metronidazole cream is the first listed.
NCT02602470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02602470 about?
NCT02602470 is a clinical study titled "Preferences & Treatment Satisfaction Drivers in Rosacea Patients". To survey patients with rosacea about their rosacea treatment preferences as well as to assess potential drivers of rosacea treatment satisfaction.
What is the current status of trial NCT02602470?
This trial is currently completed. The enrollment target is 206 participants. The study started on 2015-01-08. Estimated completion is 2016-03-10.
What interventions are being tested in trial NCT02602470?
The interventions under investigation include: Metronidazole cream (DRUG), Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251) (DRUG), Azelaic Acid Cream (DRUG), Metronidazole gel (DRUG), Metronidazole Emulsion (DRUG).
Who is sponsoring clinical trial NCT02602470?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI